CLL
Filters
All Videos
Total Health
CAR T-Cell Therapy Innovations in ALL and CLL
FEATURING
Nitin Jain
- 2 views
- March 10, 2025
Catherine Coombs
Overview of Venetoclax-Obinutuzumab in 1L CLL: Supporting Data and Clinical Pearls
- 53 views
- February 24, 2025
MyCancerHaven
The Future of CLL Treatment: Combination Therapies, Overcoming Resistance, and Emerging Strategies
FEATURING
Ravi Vij,
Adam Kittai
- 118 views
- February 14, 2025
Oncology Data Advisor
Epcoritamab in R/R CLL: Insights From the EPCORE CLL-1 Trial
FEATURING
Alexey Danilov
- 16 views
- February 14, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Clinical Application of Practice-Changing Abstracts for 1L CLL
FEATURING
Kerry Rogers,
Jennifer Woyach
- 170 views
- February 5, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: Clinical Application of Practice-Changing Abstracts for R/R CLL
FEATURING
Kerry Rogers,
Jennifer Woyach
- 26 views
- February 5, 2025
Dima El-Sharkawi
Approach to Treatment Selection and Personalization in 1L CLL
- 116 views
- January 21, 2025
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Overall Survival Outcomes of Real-World Treatment Sequences in CLL/SLL Patients
FEATURING
Joanna Rhodes
- 33 views
- January 21, 2025
Moffitt Cancer Center
Emerging Trends in the Treatment Landscape of CLL
FEATURING
Javier Pinilla-Ibarz
- 133 views
- January 21, 2025
- 1
ecancer
ASH 2024 Insights: Epcoritamab Monotherapy for Patients With R/R CLL - Updated Results From EPCORE CLL-1 Trial
FEATURING
Alexey Danilov
- 8 views
- January 17, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Patient-Reported QoL Outcomes With Venetoclax-Based 1L Combinations in CLL
FEATURING
Moritz Fürstenau
- 74 views
- January 15, 2025
2024 ASH Annual Meeting Insights Hub
ASH 2024 Summary: CLL Highlights
FEATURING
Alexey Danilov
- 265 views
- January 15, 2025
- 1
Louisville Hematology Highlights
CLL in 2024: Evolution of the Role of Novel Targeted Therapies
FEATURING
Catherine Coombs
- 137 views
- January 10, 2025
- 2
Penn Medicine Abramson Cancer Center
Pirtobrutinib Updates in CLL - Considerations for Practice
FEATURING
Jakub Svoboda
- 101 views
- January 8, 2025
- 1
The University of Kansas Cancer Center
Year in Review 2024: CLL Highlights
FEATURING
Marc Hoffmann
- 247 views
- December 27, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Sonrotoclax + Zanubrutinib in 1L CLL - Results From the BGB-11417-101 Study
FEATURING
Jake Soumerai
- 86 views
- December 20, 2024
- 1
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Zanubrutinib in Acalabrutinib-Intolerant Patients With B-Cell Malignancies
FEATURING
Mazyar Shadman
- 93 views
- December 18, 2024
- 2
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ph3 CLL12 Trial - Impact of Ibrutinib on QoL in Pts With Early-Stage, Asymptomatic CLL
FEATURING
Ellinor Goergen
- 19 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Ibrutinib or Acalabrutinib in CLL - Impact of Dose Reduction on Therapy Duration
FEATURING
Mazyar Shadman
- 70 views
- December 17, 2024
2024 ASH Annual Meeting Insights Hub
ASH 2024 Insights: Acalabrutinib, Venetoclax, Obinutuzumab in a 1L CLL Enriched for High-Risk Disease
FEATURING
Matthew Davids
- 68 views
- December 13, 2024
Fred Hutchinson Cancer Center
Current Guideline-Informed Treatment of CLL
FEATURING
Chaitra Ujjani
- 103 views
- December 13, 2024
Fox Chase Cancer Center
Pirtobrutinib in R/R B-Cell Malignancies: Newest Data From the BRUIN Trial
FEATURING
Shazia Nakhoda
- 69 views
- December 13, 2024
Nicole Lamanna
Pirtobrutinib in CLL: Current and Potential Utility in the Treatment Landscape
- 112 views
- December 3, 2024
MyCancerHaven
Conversation With Cancer Experts: Treatment of Double Refractory CLL
FEATURING
Ravi Vij,
Ryan Jacobs
- 35 views
- November 26, 2024
MyCancerHaven
Conversation With Cancer Experts: Current Treatment of R/R CLL
FEATURING
Ravi Vij,
Marc Hoffmann
- 26 views
- November 26, 2024
Danielle Brander
Choosing BTKi or BCL2i or Combination Therapy for 1L CLL
- 793 views
- November 18, 2024
- 4
City of Hope
Incorporating Pirtobrutinib and CAR-T Therapy Into CLL Practice
FEATURING
Alexey Danilov
- 46 views
- November 12, 2024
Brian Koffman
Supporting Patients With CLL: Highlighting the Importance of Community
- 32 views
- November 1, 2024
Northwestern Medicine Oncology and Hematology
Pirtobrutinib in R/R CLL: Most Recent BRUIN Trial Results
FEATURING
Shuo Ma
- 43 views
- October 29, 2024
Avirup Guha
Managing Cardiotoxicities in TKI Therapy for CLL: Atrial Fibrillation and Atrial Flutter
- 86 views
- October 23, 2024
Cleveland Clinic Taussig Cancer Institute
Updates in CLL From ASH 2023
FEATURING
Allison Winter
- 101 views
- October 22, 2024
Richard Rosenquist Brandell
Realizing Precision Medicine in CLL: Remaining Challenges and Potential Opportunities
- 73 views
- October 17, 2024
- 1
Lydia Scarfò
Managing Cardiotoxicities in BTKi Treatment for CLL: Atrial Fibrillation and Atrial Flutter
- 97 views
- October 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CLL Case Discussion: Diagnosis and Managment of Richter Syndrome
FEATURING
Mohammed Kamil Al Qayyim
- 19 views
- October 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CLL Case: Acquired Del(17p) at Relapse
FEATURING
Melis Dila Özer Çerme
- 13 views
- October 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Novel Agents in the Treatment of R/R CLL
FEATURING
Nitin Jain
- 45 views
- October 9, 2024
Masonic Cancer Center, University of Minnesota
Blood Cancers Basics
FEATURING
Zohar Sachs
- 39 views
- October 7, 2024
NYU Langone
Long-Term Efficacy of Ibrutinib in CLL
FEATURING
Marc Braunstein
- 80 views
- October 6, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in CLL: Continuous or Finite Duration Therapy
FEATURING
Nitin Jain
- 269 views
- October 6, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
MPN Case Discussion: ET With Coincindent CLL
FEATURING
Giuseppe Saglio
- 13 views
- September 27, 2024
Yale Cancer Center
Caring for Patients With Lymphoma: Using Guidelines to Improve Quality of Care
FEATURING
Scott Huntington,
Eric Winer
- 85 views
- September 11, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CLL Case Discussion: First Line Treatment Strategies
FEATURING
Damla Ortaboz
- 74 views
- September 6, 2024
Farrukh Awan
Clinical & Non-Clinical Benefits of Fixed-Duration Venetoclax Treatment in CLL
- 41 views
- September 5, 2024
MyCancerHaven
Experts Discuss Recent Developments in CLL
FEATURING
Ravi Vij,
Dahlia Sano
- 70 views
- August 30, 2024
MyCancerHaven
Evolving Concepts in CLL: Incorporating MRD
FEATURING
Ravi Vij,
Danielle Brander
- 167 views
- August 30, 2024
Nicole Lamanna
Sequencing Therapies in CLL: The Importance of First-Line Treatment Choice
- 274 views
- August 27, 2024
- 3
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Venetoclax + Ibrutinib as 1L Treatment in Patients With CLL: Meta-Analysis of RCTs
FEATURING
Ahmet Sarici
- 32 views
- August 15, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Options for Finite-Duration Therapy With BTKis in CLL
FEATURING
Ahmad Ibrahim
- 152 views
- August 13, 2024
ecancer
EHA 2024 Insights: Only Certain TP53 Mutations are Prognostic for PFS and OS in CLL
FEATURING
Consuelo Bertossi
- 56 views
- July 23, 2024
- 1
UChicago Medicine
Debates in CLL: MRD Measurement in Fixed Duration Venetoclax-Based Therapy is SOC
FEATURING
Joanna Rhodes
- 78 views
- July 22, 2024
- 2
UChicago Medicine
Debates in CLL: Measuring MRD is NOT the SOC
FEATURING
Jacob Soumerai
- 211 views
- July 22, 2024
- 2
UChicago Medicine
Targeting BTK in B-Cell NHL: Pros and Cons of Inhibitors and Degraders
FEATURING
Adam Kittai
- 50 views
- July 22, 2024
- 1
UChicago Medicine
Improving Lymphoma Outcomes: Optimizing Trial Design, Using Surrogate Endpoints, and Incorporating Guidelines
FEATURING
Andrew Zelenetz
- 116 views
- July 22, 2024
- 1
UChicago Medicine
Exploring the Value of PI3K in Lymphoma Treatment
FEATURING
Changchun Deng
- 19 views
- July 22, 2024
UChicago Medicine
The Next Frontier of Targeted Therapy in Lymphoma
FEATURING
Kami Maddocks
- 240 views
- July 22, 2024
SOHO Brazil 2024
1L Therapy in CLL: What Are the Best Options?
FEATURING
Jan Burger
- 910 views
- July 11, 2024
- 2
SOHO Brazil 2024
3L in CLL: The Best Options in a Patient Double-Refractory to Covalent BTKi and to BCL-2 Inhibitor
FEATURING
Jan Burger
- 559 views
- July 11, 2024
- 1
SOHO Brazil 2024
Single vs. Multiple Agents in 2L Therapy for CLL
FEATURING
Jan Burger
- 395 views
- July 11, 2024
- 2
Saad Kenderian
Liso-Cel in CLL: Summary of FDA Approval and Guidance on Toxicity Management
- 192 views
- July 8, 2024
- 1
Total Health
Hematologic Malignancies Update: Treatment Strategies for AML, DLBCL, MM, and CLL
FEATURING
Marcello Maria Rotta
- 351 views
- July 8, 2024
City of Hope
CLL Treatment Sequencing: The Importance of First Choice
FEATURING
Steven Rosen
- 322 views
- July 3, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Sonrotoclax + Zanubrutinib in R/R CLL/SLL
FEATURING
Stephen S. Opat
- 56 views
- July 3, 2024
City of Hope
Venetoclax vs. BTKis in CLL Treatment
FEATURING
Alexey Danilov
- 265 views
- June 28, 2024
- 1
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Advantages of Using Venetoclax-Based Therapy in High-Risk CLL
FEATURING
Catherine Coombs
- 90 views
- June 28, 2024
- 1
Cleveland Clinic Taussig Cancer Institute
R/R CLL/SLL: Overcoming Resistance to Covalent BTKi and/or BCL2 Inhibitors
FEATURING
Brian Hill
- 55 views
- June 25, 2024
2024 ASCO® Annual Meeting Insights Hub
Experts Discuss Highlights and Key Takeaways in CLL From ASCO® and EHA
FEATURING
Kerry Rogers,
Jennifer Woyach
- 325 views
- June 21, 2024
- 1
Massachusetts General Hospital Cancer Center
Practice-Changing Updates in Indolent B-Cell Lymphomas
FEATURING
Jake Soumerai
- 523 views
- June 5, 2024
- 1
Manfred Welslau
Ibrutinib for CLL: The Importance of Adherence in Optimizing Efficacy
- 248 views
- May 21, 2024
Yale Cancer Center
Case-Based Discussions in Lymphoma: 1L MCL, CD30+ T-Cell, and R/R CLL
- 102 views
- May 14, 2024
Yale Cancer Center
Yale Cancer Center Updates on B-Cell Lymphomas: Exploring MCL, DLBCL, FL, and CLL/SLL
FEATURING
Shalin Kothari
- 132 views
- May 13, 2024
MyCancerHaven
CLL and MCL: Experts Discuss the Use of Pirtobrutinib
FEATURING
Ravi Vij,
Geoffrey Shouse
- 243 views
- May 7, 2024
- 2
Indy Hematology Review
CLL: Evaluating and Therapeutic Approaches for the Management of the R/R Patient
FEATURING
Jennifer Woyach
- 297 views
- April 23, 2024
- 1
Constantine Tam
R/R CLL: A Matching-Adjusted Indirect Comparison of Zanubrutinib vs. Acalabrutinib
- 317 views
- April 22, 2024
Indy Hematology Review
Treatment Considerations for Initial Therapy of CLL
FEATURING
Peter Hillmen
- 232 views
- April 18, 2024
- 3
Indy Hematology Review
State of the Art in 2024: Emerging Therapies in Hematologic Malignancies
FEATURING
Ruemu Birhiray
- 974 views
- April 16, 2024
- 5
University of Colorado Division of Hematology
Summary and Practice Impacts of Recent Updates in B-Cell Lymphomas
FEATURING
Manali Kamdar
- 252 views
- April 8, 2024
- 1
Insights from 2023 ASH Annual Meeting
Zanubrutinib in 1L CLL: A Biomarker Analysis From the Phase 3 SEQUOIA Study
FEATURING
Paolo Ghia
- 118 views
- March 27, 2024
Fred Hutchinson Cancer Center
FDA Approval of Liso-Cel in R/R CLL: What You Need to Know
FEATURING
Mazyar Shadman
- 153 views
- March 26, 2024
SOHO Highlights: State of the Art and Next Questions
CLL: State of the Art and Next Questions
FEATURING
Nitin Jain
- 272 views
- March 25, 2024
- 1
Scripps Health
Updates in CLL: Treatment for BTKi-Refractory and BTKi/BCL-2i-Refractory Disease
FEATURING
Susan O'Brien
- 257 views
- March 18, 2024
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Practical Updates on Advances in CLL and MCL
FEATURING
Elise Chong
- 279 views
- March 13, 2024
- 1
City of Hope
Chronic GVHD: Review Advances in Prevention, Novel Endpoints, and Targeted Strategies
FEATURING
Idoroenyi Amanam
- 221 views
- March 11, 2024
- 1
Moffitt Cancer Center
Optimal Management of Patients With CLL in 2024: Interactive Cases Discussion
FEATURING
Javier Pinilla-Ibarz
- 162 views
- March 4, 2024
Louisville Hematology Highlights
Current Standard of Care and Future Directions in CLL
FEATURING
Catherine Coombs
- 143 views
- February 26, 2024
Louisville Hematology Highlights
Why Are Our Hematopoietic Stem Cells in the Bone Marrow?
FEATURING
Robert Peter Gale
- 4,721 views
- February 26, 2024
- 21
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
How I Manage Febrile Neutropenia in Patients With Cancer
FEATURING
Şiran Keske
- 77 views
- February 21, 2024
- 1
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
CLL: Future Perspectives and Unanswered Questions
FEATURING
Alessandra Ferrajoli
- 219 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Debates in CLL: The Case for Combination Therapy in 1L
FEATURING
Ahmad Ibrahim
- 39 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Debates in CLL: The Case for BTKi Monotherapy in 1L
FEATURING
Gerardo Musuraca
- 74 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
CLL Case Presentation: 72 y/o Male With Cardiac Comorbidities
FEATURING
Fatma Eda Nuhoğlu Kantarcı
- 16 views
- February 16, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
State-of-the-Art in CLL Treatment
FEATURING
Antonio Cuneo
- 521 views
- February 16, 2024
- 5
Yale Cancer Center
CLL: Genotype to Phenotype and Beyond
FEATURING
Catherine Wu
- 266 views
- February 12, 2024
Daniel Addison
Cardiovascular Considerations With (Contemporary) BTKi in the Treatment of Hematological Malignancies
- 409 views
- February 1, 2024
- 1
Insights from 2023 ASH Annual Meeting
The Best of CLL: Highlights & Key Takeaways
FEATURING
Victor Yazbeck
- 625 views
- January 24, 2024
- 2
Insights from 2023 ASH Annual Meeting
Treatment Strategies for Hematocrit Control in PV
FEATURING
Amy Zhou
- 955 views
- January 8, 2024
- 6
Insights from 2023 ASH Annual Meeting
Comparison of Venetoclax Based Treatments for Patients With R/R CLL
FEATURING
Benjamin Heyman
- 296 views
- December 22, 2023
Insights from 2023 ASH Annual Meeting
CLL/SLL: Outcomes of Pts With Richter's Transformation Without Prior Chemoimmunotherapy
FEATURING
Adam Kittai
- 364 views
- December 22, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Anti-CD19 CAR T-Cell Therapy for Richter's Transformation"
FEATURING
Adam Kittai
- 55 views
- December 22, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "MRD-Directed Therapy in CLL - Ready for Primetime?"
FEATURING
Joanna Rhodes
- 333 views
- December 22, 2023
- 2
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Efficacy of Mosunetuzumab Monotherapy in Patients With R/R Richter's Transformation"
FEATURING
Chan Cheah
- 73 views
- December 20, 2023
Insights from 2023 ASH Annual Meeting
Efficacy of Ibrutinib Arms Across ALPINE and ELEVATE-RR Trials in R/R CLL: A Matching-Adjusted Indirect Comparison
FEATURING
Mazyar Shadman
- 824 views
- December 19, 2023
- 1
Insights from 2023 ASH Annual Meeting
Impact of Ibrutinib Dose Reduction on Duration of Therapy in Patients With CLL/SLL
FEATURING
Mazyar Shadman
- 416 views
- December 19, 2023
- 4
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Effectiveness of Venetoclax-Based Therapy After BTKis in CLL"
FEATURING
Nilanjan Ghosh
- 147 views
- December 17, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "A Long-Term Analysis of Lenalidomide & Rituximab for the Treatment of CLL"
FEATURING
Chung-Jiah Chen
- 31 views
- December 17, 2023
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "A Study of Venetoclax Added to Ibrutinib to Eliminate Ibrutinib Resistance Mutations in CLL"
FEATURING
Kerry Rogers
- 70 views
- December 17, 2023
- 1
Insights from 2023 ASH Annual Meeting
TN-CLL/SLL: Combination Treatment With Sonrotoclax (BGB-11417), a 2nd-Gen BCL2i, and Zanubrutinib
FEATURING
Mary Ann Anderson
- 183 views
- December 14, 2023
Insights from 2023 ASH Annual Meeting
Prevalence and Prediction of Ruxolitinib Treatment Emergent Thrombocytopenia in Myelofibrosis
FEATURING
Douglas Tremblay
- 436 views
- December 13, 2023
- 1
Benjamin Heyman
Venetoclax Consolidation After BTKi Discontinuation for Patients With CLL
- 90 views
- December 4, 2023
Arnon Kater
iwCLL Insights: "EPCORE CLL-1 Trial - Epcoritamab in Patients With R/R CLL"
- 31 views
- December 4, 2023
PrecisCa
Expert Panel Case Discussion: 64 y/o Male With a History of CLL Presents With Thrombocytopenia
- 101 views
- December 4, 2023
5th SOHO Italy Annual Conference
How I Treat CLL at the MD Anderson Cancer Center
FEATURING
Alessandra Ferrajoli
- 604 views
- November 27, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Manage CLL in Italy
FEATURING
Antonio Cuneo
- 27 views
- November 27, 2023
5th SOHO Italy Annual Conference
Monitoring & MRD in CLL: When and Why?
FEATURING
Massimo Massaia
- 96 views
- November 27, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: Current Approach to Sequencing CLL Therapy in the Real World
FEATURING
Gianluca Gaidano
- 403 views
- November 27, 2023
- 2
5th SOHO Italy Annual Conference
SOHO Italy 2023: How to Improve the Use Novel Agents in Elderly Patients With CLL
FEATURING
Ahmad Ibrahim
- 75 views
- November 27, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: CAR T-Cell Therapy for CLL - A New Addition to our Treatment Toolbox?
FEATURING
Lorenzo Lovino
- 13 views
- November 27, 2023
5th SOHO Italy Annual Conference
SOHO Italy 2023: How I Treat CML in 2023
FEATURING
Elias Jabbour
- 154 views
- November 25, 2023
- 2
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Emerging BCL2 Inhibitors
FEATURING
Mary Ann Anderson
- 139 views
- November 21, 2023
UCI Health
Fixed-Duration Treatment in CLL: Current Considerations
FEATURING
Elizabeth Brem
- 708 views
- November 20, 2023
- 2
City of Hope
Primary Analysis of TRANSCEND CLL 004 - Liso-Cel in R/R CLL/SLL
FEATURING
Tanya Siddiqi
- 50 views
- November 6, 2023
University of Colorado Division of Hematology
Overview of Physical Exams, Labs and Diagnostic Testing for Blood Cancer Patients
FEATURING
Meredith Beaton
- 32 views
- October 24, 2023
SOHO 2023 Eleventh Annual Meeting
CLL: Next Questions
FEATURING
Nitin Jain
- 454 views
- October 19, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: How Biologic Markers Impact CLL Outcomes With Novel Therapy
FEATURING
Talha Munir
- 67 views
- October 18, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Clinical Significance of MBL
FEATURING
Sameer Parikh
- 19 views
- October 18, 2023
Adam Kittai
Highlights From iwCLL 2023: What's New and Practice Informing in CLL
- 639 views
- October 13, 2023
- 6
SOHO 2023 Eleventh Annual Meeting
Liso-Cel in R/R CLL/SLL: Primary Analysis of the Phase 1/2, Single-Arm, Multicenter TRANSCEND CLL 004 Study
FEATURING
Tanya Siddiqi
- 116 views
- October 10, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: How We Developed a Curative Therapy for CLL and Stopped Using It
FEATURING
John Seymour
- 20 views
- October 9, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023: Is Finite Duration Therapy the New Standard of Treatment in Frontline CLL?
FEATURING
Alessandra Ferrajoli
- 239 views
- October 6, 2023
SOHO 2023 Eleventh Annual Meeting
SOHO 2023 Debate: MRD+ After 1 Year of VenG in CLL - Stop or Continue Therapy?
FEATURING
Othman Al-Sawaf,
Nicole Lamanna
- 74 views
- October 6, 2023